The GLP-1 market continues to expand rapidly as pharmaceutical companies develop next-generation therapies. Originally created for blood glucose regulation in diabetes patients, GLP-1 receptor agonists are now widely recognized for their ability to produce meaningful weight loss and improve broader metabolic outcomes. JPMorgan Chase & Co. projects the broader obesity drug market could approach $200 billion by 2030 as adoption expands globally. Estimates suggest that anywhere from 25 to 30 million Americans could be using GLP-1 therapies by 2030, compared with approximately 10 million users in 2026.
Next-Generation Approaches
While market leaders Novo Nordisk and Eli Lilly dominate through injectable products, the industry is shifting toward next-generation incretin therapies focused on improving efficacy, tolerability, and convenience. Oral formulations, expanded indications, and combination metabolic therapies are becoming major priorities. Morgan Stanley projects the global GLP-1 market could approach $190 billion by 2035 as patient adoption expands and broader therapeutic applications emerge. IQVIA describes 2026 as potentially becoming the “year of the orals,” with oral GLP-1 formulations expected to significantly improve accessibility, adherence, and long-term maintenance therapy adoption.
SureNano Science is advancing GEP-44, a patented triple agonist peptide that targets GLP-1 and peptide YY receptors, designed to improve efficacy and tolerability compared to first-generation GLP-1 drugs. In preclinical testing, GEP-44 produced approximately 15% weight loss compared with roughly 9% observed with liraglutide, while food intake reductions approached 39% versus approximately 20% for the comparator. The compound reportedly avoided nausea and vomiting, common side effects with current therapies.
Recent Regulatory Advances
Eli Lilly announced FDA approval of Foundayo (orforglipron) for adults with obesity. Novo Nordisk announced that oral Ozempic tablets (semaglutide) 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes. Pfizer reported positive results from its VESPER-3 study investigating monthly maintenance dosing of PF-3944, showing patients could maintain efficacy while reducing dosing frequency fourfold.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/gnwcq-2026-5-11-the-next-generation-of-the-glp-1-revolution-is-already-underway